| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | LIMK1; LIMK; LIM domain kinase 1; LIMK-1 |
| Entrez GeneID | 3984 |
| WB Predicted band size | Calculated MW: 73 kDa; Observed MW: 73 kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human,Mouse,Rat |
| Immunogen | Synthetic peptide of human LIMK1 |
| Formulation | Purified antibody in PBS with 0.05% sodium azide,0.5%BSA and 50% glycerol. |
+ +
以下是3篇涉及LIM Kinase 1(LIMK1)抗体的研究文献摘要概括：
---
1. **文献名称**：*Regulation of actin dynamics through phosphorylation of cofilin by LIM-kinase*
**作者**：Arber, S. et al.
**摘要**：该研究首次揭示了LIMK1通过磷酸化cofilin调控肌动蛋白细胞骨架重塑的机制，实验中使用了LIMK1特异性抗体进行Western blot和免疫沉淀分析，证实LIMK1活性对神经元发育和肿瘤细胞迁移的影响。
---
2. **文献名称**：*LIM kinase 1 coordinates microtubule stability and actin polymerization in human trabecular meshwork cells*
**作者**：Yang, Y. et al.
**摘要**：研究聚焦于LIMK1在青光眼相关细胞中的功能，利用LIMK1抗体进行免疫荧光染色和蛋白质表达定量，发现LIMK1通过平衡微管稳定性和肌动蛋白聚合维持细胞形态，为治疗眼压异常提供新靶点。
---
3. **文献名称**：*LIMK1 mediates aberrant amyloid β-induced synaptic dysfunction in Alzheimer’s disease models*
**作者**：Davila, D. et al.
**摘要**：通过LIMK1抗体检测阿尔茨海默病模型中LIMK1的活性变化，研究发现β-淀粉样蛋白通过激活LIMK1导致cofilin异常磷酸化，进而破坏突触可塑性，提示LIMK1抑制剂或可改善神经退行性病变。
---
4. **文献名称**：*Targeting LIM kinase 1 inhibits tumor cell invasion and metastasis in vivo*
**作者**：Mishima, T. et al.
**摘要**：研究通过免疫组化(使用LIMK1抗体)和基因沉默技术，证明抑制LIMK1可减少乳腺癌细胞的侵袭和转移，强调了LIMK1作为癌症治疗靶点的潜力。
---
这些文献均通过LIMK1抗体验证其在细胞骨架调控、疾病机制或治疗开发中的作用。如需具体实验细节(如抗体货号或实验条件)，可进一步查阅原文。
LIM kinase 1 (LIMK1) is a serine/threonine kinase that plays a critical role in regulating actin cytoskeleton dynamics by phosphorylating and inactivating cofilin, an actin-depolymerizing protein. This phosphorylation event stabilizes actin filaments, influencing cell motility, morphology, and synaptic plasticity. LIMK1 is activated downstream of Rho GTPase signaling pathways, particularly through Rho-associated kinase (ROCK) and p21-activated kinase (PAK), linking extracellular signals to cytoskeletal reorganization. Its dysregulation has been implicated in various pathological conditions, including cancer metastasis, neurological disorders, and immune dysfunction. For instance, elevated LIMK1 expression is observed in multiple cancers, where it promotes tumor invasion by enhancing cell migration. In neurodegenerative diseases like Alzheimer’s, aberrant LIMK1 activity may contribute to synaptic deficits through dysregulated cofilin phosphorylation.
LIMK1 antibodies are essential tools for detecting and quantifying LIMK1 protein levels, phosphorylation status, and localization in cells and tissues. These antibodies enable researchers to study LIMK1's role in signaling pathways, disease mechanisms, and potential therapeutic targeting. Common applications include Western blotting, immunohistochemistry, and immunofluorescence. Specific antibodies may target distinct regions of LIMK1. such as its N-terminal LIM domains, kinase domain, or phosphorylated residues (e.g., Thr508), allowing precise analysis of its activation state. Validating antibody specificity is crucial, as cross-reactivity with the closely related LIMK2 isoform can occur. Research using LIMK1 antibodies has advanced understanding of cytoskeletal regulation in health and disease, highlighting its potential as a biomarker or therapeutic target in oncology and neurology.
×
